HA14-1

SKU: orb1224323

Description

HA14-1 a small molecule, nonpeptidic Bcl-2 antagonist that binds Bcl-2 surface pocket with binding IC50 of 9 uM, induces apoptosis of tumor cells; effectively induces apoptosis of HL-60 cells overexpressing Bcl-2 protein associated with the decrease in mitochondrial membrane potential and activation of caspase-9 followed by caspase-3; strongly induces the death of NIH 3T3 (Apaf-1(+/+)) cells.

Images & Validation

−

Key Properties

−

CAS Number	65673-63-4
MW	409.2313
Purity	>98% (HPLC)
Formula	C₁₇H₁₇BrN₂O₅
SMILES	O=C(C1=C(N)OC2=C(C=C(Br)C=C2)[C@H]1[C@H](C#N)C(OCC)=O)OCC
Target	Bcl-2
Solubility	10 mM in DMSO

Bioactivity

−

In Vivo

Swiss nude mice are challenged with BeGBM cells (104 injected s. c.). HA14-1 (400 nmol) in 100 μL free RPMI 1640-50% DMSO, or the carrier alone, is given at the site of injection once weekly from day 2 following cell injection. HA14-1 treatment does not have any significant effect on the growth of glioblastoma tumors in immunodeficient mice as monitored twice weekly by measuring the volume of the expanding tumors. Moreover, no gross organ toxicity or weight loss can be detected in mice receiving such treatment. To analyze whether HA14-1 treatment might enhance the efficiency of another antitumoral treatment, Swiss nude mice challenged with human glioblastoma multiforme cells are also given i.p. low doses of Etoposide (2.5 mg/kg in 200 μL of 0.9% NaCl 5 days a week from day 2 following cell injection) together with HA14-1 or mock treatment. Whereas Etoposide treatment is insufficient by itself to restrain the growth of glioblastoma cells, its combination with HA14-1 leads to a significant restrain on tumor growth as judged by the ability of the combined treatment to increase the doubling time of the tumor volume.

In Vitro

HA14-1 is a nonpeptidic ligand of a Bcl-2 surface pocket. HA14-1 induces the activation of Apaf-1 and caspases, possibly by binding to Bcl-2 protein and inhibiting its function. The interaction of HA14-1 with the Bcl-2 surface pocket appeared to be specific for the chemical structure of HA14-1 as a series of synthetic analogs derived from HA14-1 containing various modifications are found to have widely different Bcl-2 binding activities. To examine the effect of HA14-1 on cell viability, HL-60 cells are treated with various concentrations of HA14-1 for 4 h. HA14-1 induces the death of HL-60 cells in a dose-dependent manner. At 50 μM, HA14-1 causes the lost of viability in more than 90% of the cells. HA14-1 is a Bcl-2/Bcl-xL antagonist.

Storage & Handling

−

Storage	Storage temperature: -20°C. Stability: ≥ 2 years
Expiration Date	12 months from date of receipt.
Disclaimer	For research use only

Alternative Names

−

HA-14-1 | HA 14-1

Quality Guarantee

Explore bioreagents carefree to elevate your research. All our products are rigorously tested for performance. If a product does not perform as described on its datasheet, our scientific support team will provide expert troubleshooting, a prompt replacement, or a refund. For full details, please see our Terms & Conditions and Buying Guide. Contact us at [email protected].

Quick Database Links

Gene Symbol

Bcl-2

Documents Download

Datasheet

Product Information

Download

Request a Document

Protocol Information

Find More Protocols

HA14-1 (orb1224323)

Based on 0 reviews

Participating in our Biorbyt product reviews program enables you to support fellow scientists by sharing your firsthand experience with our products.

No reviews yet

Purity:	98.00% (May vary between batches)
CAS Number:	65673-63-4
MW:	409.23
Formula:	C₁₇H₁₇BrN₂O₅

HA14-1

Description

Images & Validation

Key Properties

Bioactivity

Storage & Handling

Alternative Names

Similar Products

HA14-1 [orb1306869]

Quality Guarantee

Quick Database Links

Documents Download

Request a Document

Protocol Information

HA14-1 (orb1224323)

Step 1: Enter information below

Step 2: Enter the in vivo formulation

Available Sizes

Email

UK Office

US Office

CN Office

Distributors